Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Generic Specialties Acquires Axcellerate Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Generic Specialties Acquires Axcellerate Pharma

Allows the company to move into the injectables market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Generic Specialties has acquired Axcellerate Pharma, a contract research organization and contract development and manufacturing organization (CRO/CDMO) focused on the development and manufacturing of sterile injectable products for generics and biologics.

Axcellerate Pharma, a specialty pharmaceutical and biologics contract manufacturer with an emphasis on clinical trials to commercial-scale manufacturing of sterile liquid, lyophilized parenterals, injectables and biologics, purchased the facilities of Enzon Pharmaceuticals in September 2013. Axcellerate says it has developed differentiated expertise to formulate and manufacture high potency and cytotoxic compounds including antibody drug conjugates (ADCs) from its FDA-approved facility in Piscataway, NJ.

“Axcellerate is a very high quality operation, has been able to build significant customer relationships and a track record for sterile products and biologics,” said Ashwin Mehta, chief executive officer, Generic Specialties. “We see this as a great platform for growth in our pharma solutions business.”

The acquisition allows Generic Specialties to move further into the injectable market segment.

“Our strong capabilities in sterile product development and in ADC product segment will allow us to offer an integrated solution to our customers,” said Mr. Mehta. “We have been impressed by the quality of the people at Axcellerate and their success in both attracting high quality business, also their track record in quality, use of isolator technology is impressive and provides a foundation for expansion of the facility to provide large scale commercial manufacturing including production of highly potent compounds.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics